Genmab (GMAB) announces topline results for epcoritamab from Phase 3 Epcore dlbcl-1 trial in patients with relapsed/refractory diffuse; said study OS did not reach statistical significance; study demonstrated an overall survival of hr: 0.96

Genmab (GMAB) announces topline results for epcoritamab from Phase 3 Epcore dlbcl-1 trial in patients with relapsed/refractory diffuse; said study OS did not reach statistical significance; study demonstrated an overall survival of hr: 0.96.

Genmab's announcement regarding the Phase 3 trial results for epcoritamab is significant, as the lack of statistical significance in overall survival may raise concerns about the efficacy of the treatment. While this could lead to a negative reaction in Genmab's share price, the specific hazard ratio of 0.96 suggests that while there is a proliferation of interest in the therapy, it may not translate into a substantial market advantage. This outcome could impact investor sentiment and affect trading in related biopharma stocks as well.